Company intelligence / Profile preview
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
- Ownership
- Private
- Development stage
- Phase 3
Overview
Jiangsu ProteLight has developed a robust pipeline centered on first-in-class antimicrobial peptides. Its lead program, peceleganan/PL‑5—a broad-spectrum topical antimicrobial peptide—has completed Phase II trials in the US and China for wound infections and entered preregistration/Phase IIIb in China. Clinical data show good efficacy with minimal systemic exposure. The company also advances additional anti-infective and oncology assets at preclinical to early clinical stages.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Peptide drugs (antimicrobial peptides, peptide therapeutics)Small molecules
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd..